Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality (AMPLCaRe)

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2013 by The Canadian College of Naturopathic Medicine
The Ottawa Hospital
Lotte & John Hecht Memorial Foundation
Gateway for Cancer Research
Information provided by (Responsible Party):
The Canadian College of Naturopathic Medicine Identifier:
First received: April 25, 2008
Last updated: October 28, 2013
Last verified: October 2013

There is evidence to support the use of melatonin, a natural health product, as an additional treatment aid for cancer patients. This study is designed to see if the daily ingestion of 20 milligrams of melatonin for one year can lower the incidence of developing lung cancer recurrence and/or death. Only patients with a diagnosis of non small cell lung cancer who are eligible for surgical resection can participate in the trial. The study will also be assessing for changes in quality of life, pain, fatigue, anxiety, sleep, and depression amongst the participants.

Condition Intervention Phase
Non Small Cell Lung Cancer
Dietary Supplement: melatonin
Dietary Supplement: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality: A Randomized Placebo Controlled Clinical Trial

Resource links provided by NLM:

Further study details as provided by The Canadian College of Naturopathic Medicine:

Primary Outcome Measures:
  • Lung Cancer Recurrence or mortality [ Time Frame: 2 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Quality of Life [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Fatigue [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Sleep [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Pain [ Time Frame: 3 months ] [ Designated as safety issue: No ]
  • Anxiety [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Depression [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • Adverse events [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  • lung cancer recurrence or mortality [ Time Frame: up to 5 years ] [ Designated as safety issue: No ]
  • blood tests to examine the effects of melatonin on the immune system [ Time Frame: baseline (before starting melatonin) and 6 months post-op ] [ Designated as safety issue: No ]

Estimated Enrollment: 640
Study Start Date: September 2007
Estimated Study Completion Date: March 2017
Estimated Primary Completion Date: February 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
To receive 20 mg of melatonin nightly for 1 year
Dietary Supplement: melatonin
20 mgs ingested nightly
Placebo Comparator: 2
To receive matched supplement to the experimental arm in same schedule
Dietary Supplement: placebo
similar to experimental in all ways except for lack of active ingredient

Detailed Description:

The trial employs a two-armed parallel placebo controlled trial design whereby patients with a diagnosis of non small cell lung cancer are randomized to receive either 20 mg of melatonin nightly or an identically matched placebo. All patients will be followed for two years with primary outcomes assessed at a two year time point and secondary outcomes evaluated throughout the course of the trial.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of non small cell lung cancer
  • Eligible for surgical resection
  • Willingness to adhere to randomized treatment
  • Availability for follow-up schedule of visits

Exclusion Criteria:

  • Taking exogenous melatonin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00668707

Contact: Andrew JE Seely, MD, PhD 613-737-8899 ext 74892
Contact: Dugald Seely, ND, MSc 613-792-1222 ext 211

Canada, British Columbia
Kelowna General Hospital Recruiting
Kelowna, British Columbia, Canada, V1Y 4N7
Principal Investigator: Bill Nelems, MD         
Sub-Investigator: Dr. Humer, MD         
Sub-Investigator: Dr. Luoma, MD         
Sub-Investigator: Dr. Jugnauth, MD         
Fraser Health Recruiting
Surrey, British Columbia, Canada, V3R 7P8
Contact: Ahmad Ashrafi, MD         
Sub-Investigator: James R Bond, MD         
Sub-Investigator: Sharone R Ong, MD         
Canada, Nova Scotia
QEII Health Sciences Centre/Capital Health Recruiting
Halifax, Nova Scotia, Canada, B3H 2Y9
Contact: Gordon Buduhan, MD         
Sub-Investigator: D Bethune, MD         
Sub-Investigator: M Johnston, MD         
Sub-Investigator: H Henteleff, MD         
Canada, Ontario
St. Joseph's/ McMaster University Recruiting
Hamilton, Ontario, Canada, L8N 4A6
Contact: John D Miller, MD         
Sub-Investigator: Yaron Shargall, MD         
Sub-Investigator: Christian Finley, MD         
Sub-Investigator: Colin Schieman, MD         
London Health Sciences Centre Recruiting
London, Ontario, Canada, N6A 5C1
Principal Investigator: Dalilah Fortin, MD         
Sub-Investigator: Richard Inculet, MD         
Sub-Investigator: Richard Malthaner, MD         
Ottawa General Hospital Recruiting
Ottawa, Ontario, Canada, K1Y 1J7
Principal Investigator: Andrew JE Seely, MD         
Sub-Investigator: Donna Maziak, MD         
Sub-Investigator: Farid Shamji, MD         
Sub-Investigator: Sudhir Sundaresan, MD         
Sub-Investigator: Scott Laurie, MD         
Sub-Investigator: Rob McRae, MD         
Sub-Investigator: Sebastien Gilbert, MD         
University Health Network Recruiting
Toronto, Ontario, Canada, M5G 1Z5
Contact: Yasufuku Kazuhiro, MD         
Sub-Investigator: Shaf Keshavjee, MD         
Sub-Investigator: Thomas Waddell, MD         
Sub-Investigator: Gail Darling, MD         
Sub-Investigator: Marc De Perrot, MD         
Sub-Investigator: Andrew Pierre, MD         
Sub-Investigator: Marcelo Cypel, MD         
Institut universitaire de cardiologie et de pneumologie de Québec Recruiting
Quebec, Canada, G1V 4G5
Contact: Jean Deslauriers, MD         
Sub-Investigator: Massimo Conti, MD         
Sub-Investigator: Eric Frechette, MD         
Sub-Investigator: Jocelyn Gregoire, MD         
Sub-Investigator: Rosaire Vaillancourt, MD         
Sponsors and Collaborators
The Canadian College of Naturopathic Medicine
The Ottawa Hospital
Lotte & John Hecht Memorial Foundation
Gateway for Cancer Research
Principal Investigator: Dugald MR Seely, ND, MSc The Canadian College of Naturopathic Medicine
Principal Investigator: Andrew JE Seely, MD The Ottawa Hospital
  More Information

Additional Information:
Responsible Party: The Canadian College of Naturopathic Medicine Identifier: NCT00668707     History of Changes
Other Study ID Numbers: 2007077-01H
Study First Received: April 25, 2008
Last Updated: October 28, 2013
Health Authority: Canada: Health Canada

Keywords provided by The Canadian College of Naturopathic Medicine:
natural health product (NHP)
lung cancer
complementary and alternative medicine (CAM)
randomized clinical trial

Additional relevant MeSH terms:
Lung Neoplasms
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Physiological Effects of Drugs
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Lung Diseases
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protective Agents
Central Nervous System Depressants
Central Nervous System Agents
Therapeutic Uses processed this record on September 16, 2014